DPYD 抗体 (AA 265-370) (Cy5.5)
Quick Overview for DPYD 抗体 (AA 265-370) (Cy5.5) (ABIN1416097)
抗原
See all DPYD 抗体适用
宿主
克隆类型
标记
应用范围
-
-
抗原表位
- AA 265-370
-
预测反应
- Human,Mouse,Rat,Dog,Cow,Sheep,Pig,Horse,Rabbit
-
纯化方法
- Purified by Protein A.
-
免疫原
- KLH conjugated synthetic peptide derived from human DPYD
-
亚型
- IgG
-
-
anti-Dihydropyrimidine Dehydrogenase (DPYD) (AA 1-110) antibody
DPYD 适用: 人 WB, ELISA, IF 宿主: 小鼠 Monoclonal 7D4 unconjugated
anti-Dihydropyrimidine Dehydrogenase (DPYD) (Internal Region) antibodyDPYD 适用: 人, 小鼠, 大鼠 WB, ELISA, IHC (p) 宿主: 兔 Polyclonal unconjugated
anti-Dihydropyrimidine Dehydrogenase (DPYD) (Internal Region) antibodyDPYD 适用: 人, 小鼠, 大鼠 WB, ELISA, IHC, ICC, IF 宿主: 兔 Polyclonal unconjugated
anti-Dihydropyrimidine Dehydrogenase (DPYD) (AA 1-173) antibodyDPYD 适用: 人 WB 宿主: 兔 Polyclonal unconjugated
anti-Dihydropyrimidine Dehydrogenase (DPYD) antibodyDPYD 适用: 人 WB, IHC (p) 宿主: 兔 Polyclonal unconjugated
anti-Dihydropyrimidine Dehydrogenase (DPYD) (AA 781-1025) antibodyDPYD 适用: 人 WB, IHC 宿主: 兔 Polyclonal unconjugated
anti-Dihydropyrimidine Dehydrogenase (DPYD) (AA 841-875) antibodyDPYD 适用: 小鼠 WB 宿主: 兔 Polyclonal RB54986 unconjugated
anti-Dihydropyrimidine Dehydrogenase (DPYD) (AA 5-152) antibodyDPYD 适用: 人 ELISA, IF 宿主: 兔 Polyclonal unconjugated
anti-Dihydropyrimidine Dehydrogenase (DPYD) (AA 169-422) antibodyDPYD 适用: 小鼠 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
anti-Dihydropyrimidine Dehydrogenase (DPYD) (AA 33-52) antibodyDPYD 适用: 人, 小鼠, 大鼠 WB 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 μg/μL
-
缓冲液
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
储存液
- ProClin
-
注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
储存条件
- -20 °C
-
储存方法
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
有效期
- 12 months
-
-
- DPYD (Dihydropyrimidine Dehydrogenase (DPYD))
-
别名
- DPYD
-
背景
-
Synonyms: DHP, DHPDHase, Dihydropyrimidine dehydrogenase [NADP+], Dihydropyrimidine dehydrogenase, Dihydrothymine dehydrogenase, Dihydrouracil dehydrogenase, DPD, DPYD, DPYD_HUMAN, MGC132008, MGC70799, OTTHUMP00000058954.
Background: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine, thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) , also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.
-
基因ID
- 1806
-
途径
- Ribonucleoside Biosynthetic Process
抗原
-
